CoreRx®a CDMO with a focus on early phase drug product development, offering state of the art facilities to support your supply chain needs throughout the entire clinical trial process. Our integrated offerings provide comprehensive services for the development, manufacturing and testing of solid, liquid and semi-solid dosage forms.
The art of drug product development is the core of what we do. We differentiate ourselves by mixing highly experienced scientists with a wide range of technologies to deliver optimal solutions to meet our clients' needs. From simple formulations to complex, delayed or targeted release dosage forms, CoreRx’s solutions maximize client investments, shorten development time and reduce overall costs.
At CoreRx, you bring us your formulation challenge and we will supply the right ingredients to ensure your product reaches its maximum potential.
CoreRX
CPhI Booth # 3G45
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.